It appears that EZH2 is up-regulated in a variety of human malignancies, including breast, colorectal, prostate, cervical and lung cancers, as well as sarcoma and glioblastoma, where its expression is associated with cancer initiation, progression, metastasis and prognosis [9, 10]. Here, EZH2 is linked to glioblastoma.